Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed sentiments. While there is optimism around EMROSI's launch and market access, concerns exist regarding generic competition affecting revenue, increased SG&A expenses, and net losses. The Q&A section highlighted management's reluctance to provide detailed guidance, which could unsettle investors. However, improved gross margins and strong initial revenue from EMROSI provide some optimism. The overall sentiment is neutral, with potential for both positive and negative outcomes depending on EMROSI's future performance.
Key Financial Performance
Net Product Revenue $15 million in Q2 2025, compared to $14.9 million in Q2 2024, a slight increase. This includes $2.8 million from the launch of EMROSI, offset by a $2.3 million decline in Accutane revenue due to generic competition.
Gross Margin 67% in Q2 2025, up from 61% in Q2 2024, driven by a favorable product sales mix, notably EMROSI and Accutane.
R&D Costs $0 in Q2 2025, compared to $900,000 in Q2 2024. The prior year's costs were related to EMROSI pre-approval project expenses.
SG&A Expenses $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, an increase of $1.6 million due to operational activities related to the launch and commercialization of EMROSI.
Net Loss $3.8 million in Q2 2025, compared to $3.4 million in Q2 2024. The increase is attributed to higher SG&A expenses.
Cash Position $20.3 million as of the end of Q2 2025, unchanged from December 31, 2024, reflecting minimal cash burn year-to-date.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EMROSI launch: EMROSI, a best-in-class oral rosacea treatment, was introduced to the market in Q2 2025. It generated $2.8 million in sales, contributing to a total net product revenue of $15 million for the quarter. Prescription volumes have shown strong uptake, with over 12,800 prescriptions generated by the end of July and a 10% share of new prescription demand among dermatology writers.
Market access for EMROSI: Payer access for EMROSI increased from 30% of commercial lives in May to 65% in July, demonstrating strong early traction in the market.
Operational efficiencies: Gross margin increased to 67% in Q2 2025 from 61% in the prior year period. Operating expenses remained mostly flat year-over-year, and cash management discipline resulted in minimal cash use for the quarter.
Focus on growth brands: The company is prioritizing the growth of EMROSI and QBREXZA to offset declines in Accutane sales due to generic competition. EMROSI is positioned as a potential standard of care for rosacea treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Accutane sales decline: Sales of Accutane have been pressured due to aggressive pricing from generic competition, leading to a decline in revenue from this product compared to the prior year period. This poses a risk to the company's revenue stability.
Generic competition: The presence of aggressive pricing from generic competitors is impacting the sales of Accutane, which could continue to affect the company's financial performance.
Increased SG&A expenses: Selling, General, and Administrative (SG&A) expenses increased by $1.6 million compared to the prior year, primarily due to operational activities related to the launch and commercialization of EMROSI. This increase in expenses could pressure profitability.
Net loss: The company reported a net loss of $3.8 million for the second quarter of 2025, slightly higher than the $3.4 million loss in the same period of 2024. This ongoing loss could impact financial sustainability.
Dependence on EMROSI's success: The company's future growth and profitability heavily rely on the success of EMROSI. Any challenges in maintaining prescription growth, payer access, or prescriber adoption could adversely impact the company's strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects strong revenue growth driven by the continued prescription ramp of EMROSI, its best-in-class oral rosacea treatment. EMROSI is anticipated to generate high contribution margins and provide significant leverage toward overall profitability and growth.
Market Penetration: EMROSI has achieved over 10% share of new prescription demand among dermatology writers within its third month of promotion. The company aims to expand the base of EMROSI prescribers and grow prescription volume further in the second half of the year.
Payer Access: Payer access for EMROSI has increased significantly from 30% of commercial lives in May to approximately 65% in July. The company plans to continue expanding payer access to facilitate prescription fulfillment.
Profitability: Journey Medical Corporation is focused on becoming sustainably EBITDA positive later in 2025, leveraging its dermatology-focused commercial organization and fixed costs.
Operational Focus: The company will prioritize expanding EMROSI's prescriber base, growing prescription volume, and converting prescription volume into revenue in the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the goal for coverage percentage by the end of the year?
A:The company has not publicly disclosed a specific target for coverage percentage by the end of the year. They are focusing on both increasing quantity coverage (currently at 65% covering over 100 million lives) and improving quality coverage by getting the drug on formularies and implementing it.
Q:How do you see gross margins evolving over the course of the year?
A:Gross margins are expected to improve as EMROSI, a low-cost product, becomes a larger percentage of the sales mix. The current gross margin represents a reasonable baseline going forward.
Q:When will the company be comfortable giving guidance for the year and next year?
A:The company plans to wait a few more quarters before providing guidance, as it is still early in the launch of the new product.
Q:What is the expected net revenue per script for EMROSI?
A:The company did not provide guidance on the average selling price (ASP) due to significant noise in the early quarters, including the use of patient assistance programs, coupons, and delays in reimbursement from payers.
Q:How should we think about summer seasonality for the rosacea market?
A:While there is some seasonality in the rosacea market, the company does not expect it to significantly impact the current pace of growth for EMROSI. Seasonality may become more of a factor as the product matures in years 2 and 3.
Q:What was the revenue for QBREXZA in the quarter?
A:The revenue for QBREXZA in the quarter was $6.9 million.
Q:Can you provide more color on payer rebating and stocking dynamics for EMROSI?
A:The company initially stocked the channel in Q1 to prepare for the launch. Payer rebating and co-pay assistance dynamics are expected to evolve over the next several quarters as more managed care plans sign up, reducing reliance on co-pay assistance programs. The company is also in late-stage discussions with two large GPOs, which will take time to implement.
Q:What is the year-end goal for market share among high-volume dermatologists and adherence trends for EMROSI?
A:The company has not provided specific year-end goals or adherence ratios but noted strong uptake and growth in prescriptions. They have increased unique prescribers from 660 to over 1,800 and are targeting 3,200 prescribers. Early feedback from patients and prescribers has been positive, and the company expects continued growth and potential conversion from ORACEA to EMROSI.
Q:Review of Unclear Management Responses
A:Management avoided giving direct answers to questions about the year-end coverage percentage target, expected net revenue per script, and specific year-end goals for market share and adherence trends. They cited the early stage of the product launch and evolving dynamics as reasons for not providing detailed guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accutane RD
Accutane competition
Accutane sale
Act Lifetime
Alliance Global
Associates SDPA
Balancing Act
Benesch CFO
CEO Director
CFO Corporate
CFO result
COO General
City ringing
Conference Participants
Conference relief
Corporate Benesch
Corporate COO
Counsel Secretary
General Counsel
Jaclyn
Journey Medical
Maraoui Co
Research Division
Russell
SGA
ability
class rosacea
leverage
plan access
prescriber
prescription trend
project
promotion product
result afternoon
rosacea treatment
DERM Transcript
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call highlights a 12% revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite regulatory approval risks, the company's financial health and operational efficiency are promising. The absence of negative insights from the Q&A further supports a positive sentiment. Given the company's growth and improved cash flow, a positive stock price movement between 2% to 8% is likely over the next two weeks.
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call reveals strong financial performance with a 10% revenue increase and improved margins. Emrosi's launch is successful, and management anticipates significant growth. Despite increased SG&A expenses, financial health is robust, with a positive cash position and working capital. The Q&A section confirms management's optimistic outlook for Emrosi's growth and improved gross margins. Overall, the positive financial metrics, optimistic guidance, and market expansion plans suggest a positive stock price movement over the next two weeks.
Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call reveals strong revenue growth driven by EMROSI, improved EBITDA, and positive cash flow. The Q&A section highlights successful prescriber expansion and revenue per script improvements, although there are concerns about gross-to-net revenue guidance and prescriber retention data. Despite these uncertainties, the overall sentiment is positive due to the strong financial metrics, optimistic guidance, and strategic focus on expanding EMROSI's market presence.
Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reflects mixed sentiments. While there is optimism around EMROSI's launch and market access, concerns exist regarding generic competition affecting revenue, increased SG&A expenses, and net losses. The Q&A section highlighted management's reluctance to provide detailed guidance, which could unsettle investors. However, improved gross margins and strong initial revenue from EMROSI provide some optimism. The overall sentiment is neutral, with potential for both positive and negative outcomes depending on EMROSI's future performance.
DERM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
